Lisata Therapeutics Inc

+0.06 (+2.04%)
5:24:34 PM EDT: $3.09 -0.16 (-4.78%)
Products, Regulatory

Caladrius Biosciences Says COVID-19 Most Negatively Impacted Registration-Eligible Trial In Japan Of Sakigake-Designated Product, Honedra

Published: 12/14/2020 13:18 GMT
(CLBS) - Caladrius Biosciences - Covid-19 Most Negatively Impacted Registration-eligible Trial in Japan of Sakigake-designated Product, Honedra.
Caladrius Biosciences Inc - Honedra Could Have an Approval Decision in Japan As Early As Late 2022 Or Early 2023.
Caladrius Biosciences - Phase 2b Freedom Trial for Clbs16 Targeted to Complete Enrollment by End of 2021; Hope to Have Top-line Data in Q3 2022.
Caladrius Biosciences Inc - Hope to Obtain Clarity on Development Plan for Clbs14 During First Half of 2021.